Carbetocin Versus Oxytocin and Hemodynamic Effects
Launched by OSLO UNIVERSITY HOSPITAL · Sep 15, 2009
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Healthy pregnant women sheduled for elective cesarean section. Invasive hemodynmaic monitoring with LiDCO Plus.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy pregnant women for planned cesarean section
- Exclusion Criteria:
- • Bleeding disorders
- • Placenta disorders
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Oslo, , Norway
Patients applied
Trial Officials
Leiv Arne Rosseland, MD PhD
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials